Company news

Ibio, Inc. (NASDAQ:IBIO) news

Ibio, Inc. news releases on 6ix. Latest, Sep 16, 2026: Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed…

Ibio, Inc. (NASDAQ:IBIO) news

Press releases & updates

Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)

iBio to Participate in the 2026 Wells Fargo Annual Healthcare Conference

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

IntraBio’s Pivotal Phase III Trial in CACNA1A-Related Disorders Is Enrolling and Is Expected to Be Over-Enrolled and Complete Recruitment in October

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

iBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical Officer

IntraBio Announces Submission of Variation Application to the European Medicines Agency for AQNEURSA® for Ataxia-Telangiectasia

iBio to Participate in Upcoming Healthcare Investor Conferences

iBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with Obesity

ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS

iBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of Directors

iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia

iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss

iBio to Participate in Upcoming Investor Conferences

iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Announces $26 Million Private Placement

iBio to Participate in the 8th Annual Evercore Healthcare Conference

IBio : Amendment to Quarterly Report (Form 10-Q/A)

iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update

iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance

iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference

iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025

iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

iBio Announces Closing of $50 Million Public Offering

iBio Announces Pricing of $50 Million Public Offering

iBio Announces Proposed Public Offering

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

iBio Reports Fiscal Third Quarter 2025 Financial Results

iBio Raises $6.2 Million Through Warrant Inducement Transaction

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline

iBio Reports Fiscal Second Quarter 2025 Financial Results

iBio Announces New Investments from Board Members and Officers

iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio

iBio Strengthens Board with Appointment of Two New Independent Directors

iBio Reports Fiscal First Quarter 2025 Financial Results

iBio Reports Fiscal Year 2024 Financial Results and Provides Corporate Update

iBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business Development

iBio Closes Sale of Manufacturing Facility in Texas

iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

iBio Announces $15.0 Million Private Placement

iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka

iBio Announces Participation in 23rd Annual PepTalk Conference

iBio, Inc. Announces Pricing of $4.5 Million Public Offering